Medicine Technology
| 5/9/2008 | TAMPA, Fla., May 9 -- Osteoarthritis is apainful and potentially debilitating condition that affects almost 50million people in the United States. It is caused by deterioration ofcartilage in bone joints. The novel investigational pain medicationtapentadol, a centrally acting oral analgesic, provided significant relieffor patients with joint-disease pain, compared... [Comments] |
| 5/9/2008 | TAMPA, Fla., May 9 -- Many strong acting painmedications have bothersome side effects. These can include nausea andvomiting with short-term use, and constipation with longer, chronic use.Such symptoms can lead patients to discontinue treatment, adding additionalcomplications to pain management for physicians. The novel investigationalmedication tapentadol, a cent... [Comments] |
| 5/9/2008 | Novel Pain Medicine Studied in Patients Following Bunionectomy TAMPA, Fla., May 9 -- Many foot-surgerypatients experience intense pain for several days following removal of abunion, one of the most common foot surgeries. The investigational painmedication tapentadol provided significant relief for patients who had thissurgery, compared to those treated with... [Comments] |
| 5/9/2008 | SEATTLE, May 9 -- The risk of the two majorprostate diseases, cancer and benign prostatic hyperplasia (BPH), can bereduced by changes in lifestyle, such as avoiding smoking, maintaining anormal weight and eating a healthy diet. Alan Kristal, Dr.P.H., associatehead of the Cancer Prevention Program at Fred Hutchinson Cancer ResearchCenter in Seattle, has conducted... [Comments] |
| 5/9/2008 | SAN DIEGO, May 9 /- Ardea Biosciences, Inc.(Nasdaq: RDEA ), a company focused on the discovery and development ofsmall- molecule therapeutics for the treatment of HIV, cancer andinflammatory diseases, including gout, today announced that John W. Beckhas been appointed Senior Vice President, Finance and Operations and ChiefFinancial Officer effective May 27, 2008.... [Comments] |
Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
| 5/9/2008 | Boosts Cytopia's development of early pipeline cancer drug candidates MELBOURNE, Australia, May 9 /- Cytopia Limited(ASX: CYT) today announced that it has entered into an anti-cancer drugdiscovery and development collaboration with Cancer Therapeutics CRC PtyLtd. This agreement leverages Cytopia's early stage drug discovery pipelineof kinase inhibitors, a class of... [Comments] |
| 5/9/2008 | - Fifth International Phase III Study Shows Positive Results with X-ray Data - NUTLEY, N.J., May 9 /- Roche today announced one-yearresults from a new two-year Phase III study showing that ACTEMRA(TM)(tocilizumab) can significantly inhibit progression of structural damage tojoints in patients with rheumatoid arthritis (RA), a critical measure o... [Comments] |
DaVita Clinical Research Completes Record Number of Renal Trials in 2007
| 5/8/2008 | Nation's Largest Renal Research Network Completes 13 Phase-I Clinical Trials; Reports Another 34 Active Trials in Late Stage Development EL SEGUNDO, Calif., May 8 /- DaVita Clinical Research(R)(DCR), a Phase I-IV clinical trial research service business specializingin renal-related drug and device research and development for FDA approval,reports it completed 13 Phase-I cl... [Comments] |
DATATRAK International Reports First Quarter Results for 2008
| 5/8/2008 | CLEVELAND, May 8 /- DATATRAK International, Inc.(Nasdaq: DATA ), a technology and services company focused on globaleClinical solutions for the clinical trials industry, today reported itsoperating results for the first quarter of 2008. For the three months ended March 31, 2008, revenue decreasedapproximately 41% to $2,088,000 and the Company reported a net loss... [Comments] |
Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
| 5/8/2008 | MIAMI, May 8 /- Globus Medical, Inc., the largestprivately held spinal implant manufacturer in the world and a recognizedleader in motion preservation technology, today announced the completion ofenrollment in its SECURE(R)-C Cervical Artificial Disc IDE study. TheSECURE(R)-C device is designed to mimic the normal motion of the spine inorder to alleviate pain and restore fu... [Comments] |
(Date:5/9/2008)...OS ANGELES, May 9 /PRNewswire/ -- Los Angeles base...ed in Asia to assess the needs of what is now,an e...yclone which,destroyed or devastated wide swaths o...n (formerly the capital Rangoon) and throughout it...inds of over 120 miles per hour and,struck communi...
(Date:5/9/2008)...VANSTON, Ill., May 9 /PRNewswire-USNewswire/ -- Me...ort to help relieve the unspeakable human,sufferin...l donation kiosks,have been developed and are bein...world of Second Life, with coordination being arra...n island,( http://slurl.com/secondlife/Simuality/1...
(Date:5/9/2008)...oalition for Iraq and Afghanistan Veterans Gather ... & Veterans Service Organizations,, CHANTILLY,...in Iraq,enters its fifth year and the U.S. death t...ch the 30,000 mark, a diverse coalition of militar...ont have organized to help,bereaved families and w...
(Date:5/9/2008)...tists find disease-resistant gene wards off fusari...lthDay News) -- A molecular-based approach to help...een identified by Dutch scientists. , In agricu...ty of plant pathogens to co-evolve along with thei...und information in the study. One way to increase ...
Breaking Medicine News(10 mins):Health News:Los Angeles Based Operation USA Appeals for Funds to Aid in Myanmar (Burmese) Cyclone Disaster (Updated) 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 3Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 4...ani Ramadoss has said that India, home to 12 milli...ation// target of 0.3 percent by 2015, five years ...e of 2020. "Currently, blindness prevalence in In... looking at the progress we are making, it would b...
...make-up using blood samples to detect certain dise...en in practice//. Now, scientists have gone a bit ... existing tests that might reveal the latent tende...stance abuse or suffer antisocial personality diso...
...ited States have developed a method that could lea...e dengue// virus. The dengue virus causes dengue ...r types of virus are all sufficiently different th...gainst one virus type are still vulnerable to infe...
...ystic kidney disease(PKD), a leading cause of fata... a research// team led by Yale biochemist Craig Cr...he National Academy of Sciences. Over 12 million ...netic disorder that causes uncontrolled growth of ...
Other Medicine News:Health News:Genetic Tests to Reveal ‘substance Abuse’ Tendenci 2Health News:Genetic Tests to Reveal ‘substance Abuse’ Tendenci 3Health News:Triptolide: A Potential Drug for Polycystic Kidney Disease 2...Western Blot): The Genetic Systems HIV-1 Western ... detection of antibodies to HIV-1. The solid phase...wn in the CEM cell line. Use of the CEM cell line,...educe cross reactivity to cell related, nonviral b...
...ded a significant layer of a safety to the nation'...s developed by Gen-Probe including target capture,... called Transcription-Mediated Amplification (TMA)... detect the presence of HIV-1 and HCV in blood don...
...V assays provide superior specificity, thereby red...tion. Vironostika HIV-1 Microelisa System is an e... of antibody to HIV-1 in serum, plasma or dried bl...a System is an enzyme-linked immuosorbent assay fo...
...Collection Device is a safe, easy, and reliable wa...raSure HIV-1 Oral Specimen Collection Device requi...ore than 99% accurate. , OraSure HIV-1 uses a spec... stick which is placed between the lower cheek and...
Medicine Products:(Date:5/9/2008)...al Phase III Study Shows Positive Results with X-r..., N.J., May 9 /- Roche today announce...tudy showing that ACTEMRA(TM),(tocilizumab) can si...ge to,joints in patients with rheumatoid arthritis...A treatment. The study also demonstrated that ACTE...
(Date:5/8/2008).../- DATATRAK International, ...ompany focused on global,eClinical solutions for t...erating results for the first quarter of 2008., F...decreased,approximately 41% to $2,088,000 and the ...0.16) per share on both a basic and diluted basis....
(Date:5/8/2008)...Newswire/ -- The Cancer Research Alliance, an,orga...r centers, is asking,303 million Americans to exer...cer research efforts this Mother,s Day through Fat...wer of One(TM)" has two key goals:,to activate Ame...ands by,joining together to exercise their collect...
(Date:5/8/2008)...ata support potential of asenapine in the treatmen...disorder, WASHINGTON, May 8 /PRNewswire-FirstCall...ay announced that an overview of asenapine clinica... the 161st Annual Meeting of the,American Psychiat... from,the studies, involving patients with bipolar...
Breaking Medicine Technology:New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7UNCOVERING THE TRUTH A Town Hall Meeting on Mental Health Parity 1306 1UNCOVERING THE TRUTH A Town Hall Meeting on Mental Health Parity 1306 2Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 1302 1Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 1302 2Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 1302 3Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives 1302 4Neurobiological Technologies Inc Reports Fourth Quarter and Fiscal Year End Financial Results for 2007 Announces 1 for 7 Reverse Stock Split 591 1Neurobiological Technologies Inc Reports Fourth Quarter and Fiscal Year End Financial Results for 2007 Announces 1 for 7 Reverse Stock Split 591 2Neurobiological Technologies Inc Reports Fourth Quarter and Fiscal Year End Financial Results for 2007 Announces 1 for 7 Reverse Stock Split 591 3Neurobiological Technologies Inc Reports Fourth Quarter and Fiscal Year End Financial Results for 2007 Announces 1 for 7 Reverse Stock Split 591 4Neurobiological Technologies Inc Reports Fourth Quarter and Fiscal Year End Financial Results for 2007 Announces 1 for 7 Reverse Stock Split 591 5Neurobiological Technologies Inc Reports Fourth Quarter and Fiscal Year End Financial Results for 2007 Announces 1 for 7 Reverse Stock Split 591 6USGS Coalition to host congressional reception 404 1USGS Coalition to host congressional reception 404 2[0] New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients[0] DATATRAK International Reports First Quarter Results for 2008[0] World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research[0] Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
...at the ASCO Cancer Conference, NORTH HOLLYWOOD, Ca...he International Myeloma Foundation (IMF)-supporti...support for myeloma patients,families, researcher...w-up to a Phase 3 multi- national clinical trial s...mproves the probability of,survival by 41%. The fo...
...Texas--(BUSINESS WIRE)--Jun 5, 2007 - Repros,Thera...ults of a,six month U.S. Phase 3 study of Androxal...al testicular function in men with,secondary hypog...ority in all the endpoints of the study, compared ...ment for low,testosterone., Study Details and Resu...
Other Medicine Technology:Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma 2Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 2Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 3Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 4Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 5| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |